Yang Jinjing, Nie Yu, Wang Fang, Hou Jianfeng, Cong Xiangfeng, Hu Shengshou, Chen Xi
Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Biochim Biophys Acta. 2013 Aug;1831(8):1386-94. doi: 10.1016/j.bbalip.2013.05.005. Epub 2013 May 25.
Earlier, our study demonstrated that lysophosphatidic acid (LPA) receptor mediated cardiomyocyte hypertrophy. However, the subtype-specific functions for LPA1 and LPA3 receptors in LPA-induced hypertrophy have not been distinguished. Growing evidence indicates that microRNAs (miRNAs) are involved in the pathogenesis of cardiac hypertrophy by down-regulating target molecules. The present work therefore aimed at elucidating the functions mediated by different subtypes of LPA receptors and investigating the modulatory role of miRNAs during LPA induced hypertrophy. Experiments were done with cultured neonatal rat cardiomyocytes (NRCMs) exposed to LPA and we showed that knockdown of LPA1 by small interfering RNA (siRNA) enhanced LPA-induced cardiomyocyte hypertrophy, whereas LPA3 silencing repressed hypertrophy. miR-23a, a pro-hypertrophic miRNA, was up-regulated by LPA in cardiomyocytes and its down-regulation reduced LPA-induced cardiomyocyte hypertrophy. Importantly, luciferase reporter assay confirmed LPA1 to be a target of miR-23a, indicating that miR-23a is involved in mediating the LPA-induced cardiomyocyte hypertrophy by targeting LPA1. In addition, knockdown of LPA3, but not LPA1, eliminated miR-23a elevation induced by LPA. And PI3K inhibitor, LY294002, effectively prevented LPA-induced miR-23a expression in cardiomyocytes, suggesting that LPA might induce miR-23a elevation by activating LPA3 and PI3K/AKT pathway. These findings identified opposite subtype-specific functions for LPA1 and LPA3 in mediating cardiomyocyte hypertrophy and indicated LPA1 to be a target of miR-23a, which discloses a link between miR-23a and the LPA receptor signaling in cardiomyocyte hypertrophy.
早期,我们的研究表明溶血磷脂酸(LPA)受体介导心肌细胞肥大。然而,LPA1和LPA3受体在LPA诱导的肥大中的亚型特异性功能尚未明确区分。越来越多的证据表明,微小RNA(miRNA)通过下调靶分子参与心脏肥大的发病机制。因此,本研究旨在阐明不同亚型的LPA受体介导的功能,并研究miRNA在LPA诱导的肥大过程中的调节作用。我们对培养的新生大鼠心肌细胞(NRCMs)进行了实验,结果表明,用小干扰RNA(siRNA)敲低LPA1可增强LPA诱导的心肌细胞肥大,而沉默LPA3则可抑制肥大。促肥大miRNA miR-23a在心肌细胞中被LPA上调,其下调可减轻LPA诱导的心肌细胞肥大。重要的是,荧光素酶报告基因检测证实LPA1是miR-23a的靶标,表明miR-23a通过靶向LPA1参与介导LPA诱导的心肌细胞肥大。此外,敲低LPA3而非LPA1可消除LPA诱导的miR-23a升高。PI3K抑制剂LY294002可有效阻止LPA诱导的心肌细胞中miR-23a的表达,提示LPA可能通过激活LPA3和PI3K/AKT信号通路诱导miR-23a升高。这些发现确定了LPA1和LPA3在介导心肌细胞肥大中的相反亚型特异性功能,并表明LPA1是miR-23a的靶标,这揭示了miR-23a与心肌细胞肥大中LPA受体信号传导之间的联系。